+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Multiple Myeloma Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026

  • ID: 5401572
  • Report
  • August 2021
  • Region: Global
  • 146 pages
  • IMARC Group

FEATURED COMPANIES

  • Amgen Inc.
  • Daiichi Sankyo Company
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Pharma Mar S.A.
The global multiple myeloma drugs market exhibited strong growth during 2015-2020. Multiple myeloma, or Kahler's disease, refers to a form of blood cancer that primarily affects the plasma cells. Some of the most common types of multiple myeloma drugs include chemotherapeutic agents, corticosteroids and immunomodulatory agents. These pharmaceutical drugs aid in promoting bone healing, prevent hypercalcemia, bone fracture, spinal cord compression and anemia, while minimizing the need for chemotherapy. The chemotherapeutic agents include various anthracycline antibiotics and alkylating agents, such as melphalan, doxorubicin, vincristine and liposomal doxorubicin. The targeted therapy drugs include proteasome inhibitor, such as bortezomib, and various other compounds, including dexamethasone, prednisone and thalidomide.

Significant developments in the healthcare sector, along with the increasing prevalence of hematological cancer, is one of the key factors driving the growth of the market. Multiple myeloma is usually caused by specific genetic abnormalities, and the treatment of this disease involves drugs that modulate the immune system and aid in enhancing the efficiency of chemotherapies, radiation therapies, stem cell transplants and platelet transfusion. Furthermore, rising consumer awareness regarding the benefits of biologic therapy drugs, which utilize the body’s immune system to identify and attack the myeloma cells, is also providing a boost to the market growth. Additionally, various technological advancements, such as the development of microRNA therapeutics and nanomedicines for the treatment of multiple myeloma, is acting as another growth-inducing factor. These medicines are used to facilitate the delivery of macromolecular agents into the bone marrow and catalyze antitumor responses. Other factors, including the rising healthcare expenditures and extensive research and development (R&D) activities in the field of medical sciences, are projected to drive the market further. Looking forward, the publisher expects the global multiple myeloma drugs market to grow at a CAGR of around 10% during the forecast period (2021-2026).

Breakup by Therapy:

  • Targeted Therapy
  • Biologic Therapy
  • Chemotherapy
  • Others

Breakup by Drug Type:

  • Immunomodulatory Drugs
  • Proteasome Inhibitors
  • Histone Deacetylase Inhibitors
  • Monoclonal Antibody Drugs
  • Steroids
  • Others

Breakup by End-User:

  • Men
  • Women

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Amgen Inc., Bristol-Myers Squibb Company, Daiichi Sankyo Company, Genzyme Corporation (Sanofi-Aventis), Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, Pfizer Inc., Pharma Mar S.A., Takeda Pharmaceutical Company Limited., Teva Pharmaceutical Industries Ltd., etc.

Key Questions Answered in This Report:

  • How has the global multiple myeloma drugs market performed so far and how will it perform in the coming years?
  • What are the key regional markets?
  • What has been the impact of COVID-19 on the global multiple myeloma drugs market?
  • What is the breakup of the market based on the therapy?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the end-user?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global multiple myeloma drugs market and who are the key players?
  • What is the degree of competition in the industry?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Amgen Inc.
  • Daiichi Sankyo Company
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Pharma Mar S.A.
1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction
4.1 Overview
4.2 Key Industry Trends

5 Global Multiple Myeloma Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Therapy
6.1 Targeted Therapy
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Biologic Therapy
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Chemotherapy
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Others
6.4.1 Market Trends
6.4.2 Market Forecast

7 Market Breakup by Drug Type
7.1 Immunomodulatory Drugs
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Proteasome Inhibitors
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Histone Deacetylase Inhibitors
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Monoclonal Antibody Drugs
7.4.1 Market Trends
7.4.2 Market Forecast
7.5 Steroids
7.5.1 Market Trends
7.5.2 Market Forecast
7.6 Others
7.6.1 Market Trends
7.6.2 Market Forecast

8 Market Breakup by End-User
8.1 Men
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Women
8.2.1 Market Trends
8.2.2 Market Forecast

9 Market Breakup by Distribution Channel
9.1 Hospital Pharmacies
9.1.1 Market Trends
9.1.2 Market Forecast
9.2 Retail Pharmacies
9.2.1 Market Trends
9.2.2 Market Forecast
9.3 Online Pharmacies
9.3.1 Market Trends
9.3.2 Market Forecast
9.4 Others
9.4.1 Market Trends
9.4.2 Market Forecast

10 Market Breakup by Region
10.1 North America
10.1.1 United States
10.1.1.1 Market Trends
10.1.1.2 Market Forecast
10.1.2 Canada
10.1.2.1 Market Trends
10.1.2.2 Market Forecast
10.2 Asia Pacific
10.2.1 China
10.2.1.1 Market Trends
10.2.1.2 Market Forecast
10.2.2 Japan
10.2.2.1 Market Trends
10.2.2.2 Market Forecast
10.2.3 India
10.2.3.1 Market Trends
10.2.3.2 Market Forecast
10.2.4 South Korea
10.2.4.1 Market Trends
10.2.4.2 Market Forecast
10.2.5 Australia
10.2.5.1 Market Trends
10.2.5.2 Market Forecast
10.2.6 Indonesia
10.2.6.1 Market Trends
10.2.6.2 Market Forecast
10.2.7 Others
10.2.7.1 Market Trends
10.2.7.2 Market Forecast
10.3 Europe
10.3.1 Germany
10.3.1.1 Market Trends
10.3.1.2 Market Forecast
10.3.2 France
10.3.2.1 Market Trends
10.3.2.2 Market Forecast
10.3.3 United Kingdom
10.3.3.1 Market Trends
10.3.3.2 Market Forecast
10.3.4 Italy
10.3.4.1 Market Trends
10.3.4.2 Market Forecast
10.3.5 Spain
10.3.5.1 Market Trends
10.3.5.2 Market Forecast
10.3.6 Russia
10.3.6.1 Market Trends
10.3.6.2 Market Forecast
10.3.7 Others
10.3.7.1 Market Trends
10.3.7.2 Market Forecast
10.4 Latin America
10.4.1 Brazil
10.4.1.1 Market Trends
10.4.1.2 Market Forecast
10.4.2 Mexico
10.4.2.1 Market Trends
10.4.2.2 Market Forecast
10.4.3 Others
10.4.3.1 Market Trends
10.4.3.2 Market Forecast
10.5 Middle East and Africa
10.5.1 Market Trends
10.5.2 Market Breakup by Country
10.5.3 Market Forecast

11 SWOT Analysis
11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis
13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Indicators

15 Competitive Landscape
15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
15.3.1 Amgen Inc.
15.3.1.1 Company Overview
15.3.1.2 Product Portfolio
15.3.1.3 Financials
15.3.1.4 SWOT Analysis
15.3.2 Bristol-Myers Squibb Company
15.3.2.1 Company Overview
15.3.2.2 Product Portfolio
15.3.2.3 Financials
15.3.2.4 SWOT Analysis
15.3.3 DAIICHI SANKYO COMPANY
15.3.3.1 Company Overview
15.3.3.2 Product Portfolio
15.3.3.3 Financials
15.3.3.4 SWOT Analysis
15.3.4 Genzyme Corporation (Sanofi-Aventis)
15.3.4.1 Company Overview
15.3.4.2 Product Portfolio
15.3.4.3 SWOT Analysis
15.3.5 Johnson & Johnson Services Inc.
15.3.5.1 Company Overview
15.3.5.2 Product Portfolio
15.3.5.3 Financials
15.3.5.4 SWOT Analysis
15.3.6 Merck & Co. Inc.
15.3.6.1 Company Overview
15.3.6.2 Product Portfolio
15.3.6.3 Financials
15.3.6.4 SWOT Analysis
15.3.7 Novartis AG
15.3.7.1 Company Overview
15.3.7.2 Product Portfolio
15.3.7.3 Financials
15.3.7.4 SWOT Analysis
15.3.8 Pfizer Inc.
15.3.8.1 Company Overview
15.3.8.2 Product Portfolio
15.3.8.3 Financials
15.3.8.4 SWOT Analysis
15.3.9 Pharma Mar S.A.
15.3.9.1 Company Overview
15.3.9.2 Product Portfolio
15.3.9.3 Financials
15.3.10 Takeda Pharmaceutical Company Limited.
15.3.10.1 Company Overview
15.3.10.2 Product Portfolio
15.3.10.3 Financials
15.3.10.4 SWOT Analysis
15.3.11 Teva Pharmaceutical Industries Ltd.
15.3.11.1 Company Overview
15.3.11.2 Product Portfolio
15.3.11.3 Financials
15.3.11.4 SWOT Analysis

List of Figures
Figure 1: Global: Multiple Myeloma Drugs Market: Major Drivers and Challenges
Figure 2: Global: Multiple Myeloma Drugs Market: Sales Value (in Billion US$), 2015-2020
Figure 3: Global: Multiple Myeloma Drugs Market: Breakup by Therapy (in %), 2020
Figure 4: Global: Multiple Myeloma Drugs Market: Breakup by Drug Type (in %), 2020
Figure 5: Global: Multiple Myeloma Drugs Market: Breakup by End-User (in %), 2020
Figure 6: Global: Multiple Myeloma Drugs Market: Breakup by Distribution Channel (in %), 2020
Figure 7: Global: Multiple Myeloma Drugs Market: Breakup by Region (in %), 2020
Figure 8: Global: Multiple Myeloma Drugs Market Forecast: Sales Value (in Billion US$), 2021-2026
Figure 9: Global: Multiple Myeloma Drugs (Targeted Therapy) Market: Sales Value (in Million US$), 2015 & 2020
Figure 10: Global: Multiple Myeloma Drugs (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 11: Global: Multiple Myeloma Drugs (Biologic Therapy) Market: Sales Value (in Million US$), 2015 & 2020
Figure 12: Global: Multiple Myeloma Drugs (Biologic Therapy) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 13: Global: Multiple Myeloma Drugs (Chemotherapy) Market: Sales Value (in Million US$), 2015 & 2020
Figure 14: Global: Multiple Myeloma Drugs (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 15: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2015 & 2020
Figure 16: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 17: Global: Multiple Myeloma Drugs (Immunomodulatory Drugs) Market: Sales Value (in Million US$), 2015 & 2020
Figure 18: Global: Multiple Myeloma Drugs (Immunomodulatory Drugs) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 19: Global: Multiple Myeloma Drugs (Proteasome Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
Figure 20: Global: Multiple Myeloma Drugs (Proteasome Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 21: Global: Multiple Myeloma Drugs (Histone Deacetylase Inhibitors) Market: Sales Value (in Million US$), 2015 & 2020
Figure 22: Global: Multiple Myeloma Drugs (Histone Deacetylase Inhibitors) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 23: Global: Multiple Myeloma Drugs (Monoclonal Antibody Drugs) Market: Sales Value (in Million US$), 2015 & 2020
Figure 24: Global: Multiple Myeloma Drugs (Monoclonal Antibody Drugs) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 25: Global: Multiple Myeloma Drugs (Steroids) Market: Sales Value (in Million US$), 2015 & 2020
Figure 26: Global: Multiple Myeloma Drugs (Steroids) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 27: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2015 & 2020
Figure 28: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 29: Global: Multiple Myeloma Drugs (Men) Market: Sales Value (in Million US$), 2015 & 2020
Figure 30: Global: Multiple Myeloma Drugs (Men) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 31: Global: Multiple Myeloma Drugs (Women) Market: Sales Value (in Million US$), 2015 & 2020
Figure 32: Global: Multiple Myeloma Drugs (Women) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 33: Global: Multiple Myeloma Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2015 & 2020
Figure 34: Global: Multiple Myeloma Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 35: Global: Multiple Myeloma Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2015 & 2020
Figure 36: Global: Multiple Myeloma Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 37: Global: Multiple Myeloma Drugs (Online Pharmacies) Market: Sales Value (in Million US$), 2015 & 2020
Figure 38: Global: Multiple Myeloma Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 39: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million US$), 2015 & 2020
Figure 40: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 41: North America: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 42: North America: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 43: United States: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 44: United States: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 45: Canada: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 46: Canada: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 47: Asia Pacific: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 48: Asia Pacific: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 49: China: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 50: China: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 51: Japan: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 52: Japan: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 53: India: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 54: India: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 55: South Korea: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 56: South Korea: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 57: Australia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 58: Australia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 59: Indonesia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 60: Indonesia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 61: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 62: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 63: Europe: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 64: Europe: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 65: Germany: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 66: Germany: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 67: France: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 68: France: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 69: United Kingdom: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 70: United Kingdom: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 71: Italy: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 72: Italy: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 73: Spain: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 74: Spain: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 75: Russia: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 76: Russia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 77: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 78: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 79: Latin America: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 80: Latin America: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 81: Brazil: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 82: Brazil: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 83: Mexico: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 84: Mexico: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 85: Others: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 86: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 87: Middle East and Africa: Multiple Myeloma Drugs Market: Sales Value (in Million US$), 2015 & 2020
Figure 88: Middle East and Africa: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million US$), 2021-2026
Figure 89: Global: Multiple Myeloma Drugs Industry: SWOT Analysis
Figure 90: Global: Multiple Myeloma Drugs Industry: Value Chain Analysis
Figure 91: Global: Multiple Myeloma Drugs Industry: Porter’s Five Forces Analysis

List of Tables
Table 1: Global: Multiple Myeloma Drugs Market: Key Industry Highlights, 2020 and 2026
Table 2: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Therapy (in Million US$), 2021-2026
Table 3: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2021-2026
Table 4: Global: Multiple Myeloma Drugs Market Forecast: Breakup by End-User (in Million US$), 2021-2026
Table 5: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2021-2026
Table 6: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Region (in Million US$), 2021-2026
Table 7: Global: Multiple Myeloma Drugs Market Structure
Table 8: Global: Multiple Myeloma Drugs Market: Key Players
Note: Product cover images may vary from those shown
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo Company
  • Genzyme Corporation (Sanofi-Aventis)
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Pharma Mar S.A.
  • Takeda Pharmaceutical Company Limited.
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll